Differentiating GAD65 Antibodies in Stiff Person Syndrome versus Diabetes
Key Differences in GAD65 Antibody Characteristics
- The American Diabetes Association recommends considering GAD65 antibody titers and epitope recognition patterns to differentiate Stiff Person Syndrome (SPS) from diabetes, with SPS patients exhibiting higher titers and unique epitope recognition patterns 1, 2
Clinical Manifestations
- In SPS, GAD65 antibody-mediated inhibition of GAD leads to decreased GABA levels in the CNS, resulting in progressive spasmodic muscular rigidity and painful muscle spasms 1, 2
- The presence of GAD65 antibodies in diabetes is associated with autoimmune destruction of pancreatic β-cells, according to the American Association of Clinical Endocrinologists 3
Diagnostic Approach
- The American College of Physicians recommends standardized islet autoantibody tests, including GAD65 antibodies, for diabetes classification in adults with overlapping phenotypic risk factors 4
- For suspected SPS, both serum and CSF should be tested for GAD65 antibodies, as recommended by the European Federation of Neurological Societies 2
Clinical Implications
- Patients with SPS should be monitored for development of diabetes, and patients with high GAD65 antibody titers and neurological symptoms should be evaluated for SPS, according to the National Institute of Neurological Disorders and Stroke 1, 2
- Recognition of the specific antibody pattern can guide appropriate treatment, with SPS often requiring immunotherapy targeting the neurological autoimmunity, as recommended by the American Academy of Neurology 2